We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
5-Fluorouracil, Adriamycin, Cyclophosphamide (FAC) vs. 5-Fluorouracil, Epirubicin, Cyclophosphamide (FEC) in Metastatic Breast Cancer.
- Authors
Lopez, Massimo; Papaldo, Paola; Di Lauro, Luigi; Vici, Patrizia; Carpano, Silvia; Conti, Ettore M.S.
- Abstract
94 evaluable patients with metastatic breast cancer were randomly assigned to 5-fiuorouracil, adriamycin, and cyclophosphamide (FAC) or 5-fluorouracil, epirubicin, and cyclophosphamide (FEC), with cycles repeated every 3 weeks. The objective response rate to FAC was 46% versus 44% to FEC. There was no significant difference in the median duration of response and median survival for the two regimens. Toxicity was more frequent and more pronounced in patients receiving FAC. Results indicate therapeutic equivalence of the two regimens and reduced toxicity of the epirubicin arm. Copyright © 1989 S. Karger AG, Basel
- Publication
Oncology, 1989, Vol 46, Issue 1, p1
- ISSN
0030-2414
- Publication type
Article
- DOI
10.1159/000226671